This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NAMSA Sponsoring Conference On Best Practices For Biocompatibility And Performance Of Medical Devices

NORTHWOOD, Ohio, Jan. 8, 2013 /PRNewswire/ -- NAMSA, the world's leading medical device research organization, is sponsoring a comprehensive symposium based on the definitive new book, "Biocompatibility and Performance of Medical Devices," assembled by ANSM expert Dr. Jean-Pierre Boutrand, in London, England, February 12-14. This one-of-a-kind event offers attendees crucial insights on medical device testing.

The two-day symposium is a unique gathering of international thought leaders representing a diverse mix of professionals in research and development, quality assurance, regulatory affairs and product engineering, and is designed for professionals in these and other device-related positions.

"Implant and device manufacturers are increasingly facing the challenge of proving their products are safe, biocompatible and will perform as expected," said Dr. Boutrand. "This event will prove an essential guide to the performance analysis of medical devices and will feature expertise for every medical specialty – from cardiology to bone healing, tissue engineering to combined products."

Attendees will hear from multiple members of the international team who co-authored the book on critical topics such as biocompatibility evaluation and overcoming negative test results in manufacture. Event speakers include:

Dr. Jean-Pierre Boutrand, NAMSA Professor David F. Williams, Wake Forest Institute of Regenerative MedicineDr. Kelly Coleman, Medtronic, Inc. Dr. David Albert, NAMSA Dr. Ronald Brown, U.S. Food and Drug AdministrationDr. Joseph Carraway, NAMSA Michael F. Wolf, Medtronic, Inc. Dr. David Parente, Ecolab Dr. Roy Martin, NAMSA Dr. Andrew Lewis, Biocompatibles UK Ltd Dr. Adrian Keene, SGS An Liu, NAMSA Professor Jiao Sun, Shanghai Biomaterials Research & Testing Center, Shanghai Jiaotong University

"NAMSA's thrilled to support this rare gathering of international thought leaders sharing insights on vital topics affecting our industry," said Terry Langenderfer, NAMSA's director or global marketing. "Attendees will learn more about the best options, techniques and methods for proving biocompatibility and performance of medical devices from those who have succeeded in these areas."

A second symposium will be held in Minneapolis, Minn., USA, May 14-16. For more information on this international event, visit www.bpmds2013.com and follow event updates on Twitter at www.twitter.com/MedDeviceTests.

About NAMSA NAMSA ( www.namsa.com) is a global medical device research organization providing a comprehensive range of services to prove efficacy, non-clinical and clinical safety of medical devices, IVDs and combination products. For more than 45 years, NAMSA clients have utilized its testing and consulting services to bring safe and effective therapies to market.

Contact InformationFor further information about NAMSA, contact: Sean HamiltonMarketing Communications Manager419.662.4846 shamilton@namsa.com

SOURCE NAMSA

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs